{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:02:06Z","timestamp":1792425726417,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":55,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018748","name":"argenx nv","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011944","name":"School of Public Health, University of California Berkeley","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jns.2022.120480","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T18:31:41Z","timestamp":1666981901000},"page":"120480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Real-world utilization patterns of intravenous immunoglobulin in adults with generalized myasthenia gravis in the United States"],"prefix":"10.1016","volume":"443","author":[{"given":"Cynthia Z.","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Gelinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuebing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Brauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpit","family":"Bhuwalka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jns.2022.120480_bb0005","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jns.2022.120480_bb0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jns.2022.120480_bb0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","article-title":"Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study","volume":"205","author":"Hendricks","year":"2019","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.jns.2022.120480_bb0020","author":"Howard"},{"issue":"1\u20132","key":"10.1016\/j.jns.2022.120480_bb0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jns.2007.04.045","article-title":"Myasthenic crisis: guidelines for prevention and treatment","volume":"261","author":"Jani-Acsadi","year":"2007","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.jns.2022.120480_bb0030","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120480_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116648","article-title":"Maintenance immunosuppression in myasthenia gravis, an update","volume":"410","author":"Morren","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.jns.2022.120480_bb0040","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/WCO.0000000000000858","article-title":"Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies","volume":"33","author":"Dalakas","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jns.2022.120480_bb0045","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3389\/fneur.2020.00604","article-title":"A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature","volume":"11","author":"Farrugia","year":"2020","journal-title":"Front. Neurol."},{"issue":"12","key":"10.1016\/j.jns.2022.120480_bb0050","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.jns.2022.120480_bb0055","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/1744666X.2022.2082946","article-title":"Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis","volume":"18","author":"Dalakas","year":"2022","journal-title":"Expert. Rev. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.jns.2022.120480_bb0060","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.jns.2022.120480_bb0065","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.jns.2022.120480_bb0070","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40120-021-00285-w","article-title":"The lived experience of myasthenia gravis: a patient-led analysis","volume":"10","author":"Law","year":"2021","journal-title":"Neurol. Ther."},{"issue":"2","key":"10.1016\/j.jns.2022.120480_bb0075","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology \u2013 mode of action and clinical efficacy","volume":"11","author":"L\u00fcnemann","year":"2015","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2022.120480_bb0080","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00002826-200105000-00010","article-title":"The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis","volume":"24","author":"Hilkevich","year":"2001","journal-title":"Clin. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.jns.2022.120480_bb0085","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/ene.14547","article-title":"Chronic immunoglobulin maintenance therapy in myasthenia gravis","volume":"28","author":"Alcantara","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2022.120480_bb0090","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/mus.24259","article-title":"Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation","volume":"50","author":"Eienbr\u00f6ker","year":"2014","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jns.2022.120480_bb0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0303-8467(02)00017-3","article-title":"Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis","volume":"105","author":"Wegner","year":"2002","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jns.2022.120480_bb0100","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-021-10544-3","article-title":"Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis","author":"Wilf-Yarkoni","year":"2021","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2022.120480_bb0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2013.10.043","article-title":"Maintenance IVIg therapy in myasthenia gravis does not affect disease activity","volume":"338","author":"Hellmann","year":"2014","journal-title":"J. Neurol. Sci."},{"issue":"11","key":"10.1016\/j.jns.2022.120480_bb0110","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/j.jns.2022.120480_bb0115","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120480_bb0120","series-title":"Efficacy and safety of IGIV-C in corticosteroid dependent patients with generalized myasthenia gravis","year":"2022"},{"issue":"5","key":"10.1016\/j.jns.2022.120480_bb0125","doi-asserted-by":"crossref","DOI":"10.17161\/rrnmf.v2i5.15806","article-title":"Practice patterns in the management of myasthenia gravis: a cross-sectional survey of neurologists in the United States","volume":"2","author":"Bril","year":"2021","journal-title":"RRNMF Neuromusc. J."},{"key":"10.1016\/j.jns.2022.120480_bb0130","article-title":"Real-world healthcare resource utilization and cost burden assessment for adults with generalized myasthenia gravis in the United States","volume":"12","author":"Phillips","year":"2021","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.jns.2022.120480_bb0135","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/mus.27526","article-title":"Validation of myasthenia gravis diagnosis in the older Medicare population","volume":"65","author":"Lee","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2022.120480_bb0140","series-title":"Databases, Tables & Calculators by Subject, CPI for All Urban Consumers (CPI-U)","year":"2022"},{"issue":"5","key":"10.1016\/j.jns.2022.120480_bb0145","article-title":"Myasthenia gravis and its comorbidities","volume":"6","author":"D\u00edaz","year":"2015","journal-title":"J. Neurol. Neurophysiol."},{"issue":"1","key":"10.1016\/j.jns.2022.120480_bb0150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s13760-019-01102-w","article-title":"A study of comorbidities in myasthenia gravis","volume":"120","author":"Misra","year":"2020","journal-title":"Acta Neurol. Belg."},{"issue":"6","key":"10.1016\/j.jns.2022.120480_bb0155","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/mus.22212","article-title":"Cost analysis of myasthenia gravis from a large US insurance database","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2022.120480_bb0160","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.jns.2022.120480_bb0165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cen3.12180","article-title":"Japanese clinical guidelines for myasthenia gravis: putting into practice","volume":"6","author":"Murai","year":"2015","journal-title":"Clin. Exp. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.jns.2022.120480_bb0170","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/CND.0000000000000342","article-title":"Methotrexate as a steroid-sparing agent in myasthenia gravis: a preliminary retrospective study","volume":"23","author":"Rodolico","year":"2021","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"10.1016\/j.jns.2022.120480_bb0175","series-title":"Rituximab for the Treatment of Myasthenia Gravis: A 2021 Update, Canadian Agency for Drugs and Technologies in Health","author":"Young","year":"2021"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22003422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22003422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:00:43Z","timestamp":1758384043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X22003422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":35,"alternative-id":["S0022510X22003422"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2022.120480","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world utilization patterns of intravenous immunoglobulin in adults with generalized myasthenia gravis in the United States","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2022.120480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120480"}}